Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
McKinsey
Dow
Harvard Business School
Mallinckrodt

Last Updated: November 30, 2021

DrugPatentWatch Database Preview

MEGESTROL ACETATE Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Megestrol Acetate patents expire, and what generic alternatives are available?

Megestrol Acetate is a drug marketed by Akorn, Breckenridge, Hikma Pharms, Par Pharm, Pharm Assoc, Teva Pharms, Twi Pharms, Wockhardt Bio Ag, Barr, Teva, and Usl Pharma. and is included in fifteen NDAs.

The generic ingredient in MEGESTROL ACETATE is megestrol acetate. There are eighteen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the megestrol acetate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Megestrol Acetate

A generic version of MEGESTROL ACETATE was approved as megestrol acetate by PAR PHARM on August 8th, 1988.

  Free Forever Trial

Drug patent expirations by year for MEGESTROL ACETATE
Drug Prices for MEGESTROL ACETATE

See drug prices for MEGESTROL ACETATE

Recent Clinical Trials for MEGESTROL ACETATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University Health Network, TorontoPhase 1
Xiaojun ChenPhase 2/Phase 3
Huashan HospitalPhase 2/Phase 3

See all MEGESTROL ACETATE clinical trials

Pharmacology for MEGESTROL ACETATE
Drug ClassProgestin
Medical Subject Heading (MeSH) Categories for MEGESTROL ACETATE
Paragraph IV (Patent) Challenges for MEGESTROL ACETATE
Tradename Dosage Ingredient NDA Submissiondate
MEGACE ES SUSPENSION;ORAL megestrol acetate 021778 2011-04-27
MEGACE SUSPENSION;ORAL megestrol acetate 020264

US Patents and Regulatory Information for MEGESTROL ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Akorn MEGESTROL ACETATE megestrol acetate SUSPENSION;ORAL 203960-001 Jun 9, 2017 AB RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Twi Pharms MEGESTROL ACETATE megestrol acetate SUSPENSION;ORAL 203139-001 Aug 27, 2014 AB RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Par Pharm MEGESTROL ACETATE megestrol acetate SUSPENSION;ORAL 075671-001 Jul 25, 2001 AB RX No Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Boehringer Ingelheim
Merck
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.